Tamnorzatinib

DB19201InvestigationalSmall molecule

Tamnorzatinib is under investigation in clinical trial NCT03176277 (A Study of ONO-7475 in Patients With Acute Leukemias).

Chemical structure of Tamnorzatinib
Formula / weight
C32H26N4O6 · 562.582 g/mol (avg)
Also known as
3-quinolinecarboxamide, n-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl- · N-(5-((6,7-dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide
Code names
ONO-7475

Resolves to

Compound
UNII0VCB95RHRVCAS1646839-59-9
Structure
InChIKeyWHMMKPWGWNYYFE-UHFFFAOYSA-NSMILESCOC1=CC2=NC=CC(OC3=CC=C(NC(=O)C4=CC5=C(CCCC5=O)N(C5=CC=CC=C5)C4=O)N=C3)=C2C=C1OC
Targets
P30530AXLQ12866MERTK

What you can answer from here — as of April 23, 2025

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
4Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Tamnorzatinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In